Curasight today announced that it will expand its focus area for its two modalities, uTRACE (diagnostics) and uTREAT (therapy). Two recent publications made by researchers at the Danish Rigshospitalet underscored the potential of Curasight’s technology when applied to Neuroendocrine tumors (NET) and head and neck cancer. As a result, Curasight is now investing into those two indications too, which adds further breath to its pipeline.

Link to the analysis